Clinical trial
A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope Folate Receptor Alpha Peptide Vaccine Used in Combination With Cyclophosphamide in Subjects Previously Treated for Breast or Ovarian Cancer
NCT01606241 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Trial of the Safety and Immunogenicity of a Multi-epitope Folate Receptor Alpha Peptide Vaccine Used in Combination With Cyclophosphamide in Subjects Previously Treated for Breast or Ovarian Cancer
- Lead sponsor
- Mayo Clinic
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 24, 2012
- Completion date
- March 9, 2018
- Enrollment
- 24 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent breast carcinoma, recurrent fallopian tube carcinoma, recurrent ovarian carcinoma, recurrent primary peritoneal carcinoma, stage iia breast cancer, stage iia fallopian tube cancer, stage iia ovarian cancer, stage iib breast cancer, stage iib fallopian tube cancer, stage iib ovarian cancer, stage iic fallopian tube cancer, stage iic ovarian cancer, stage iiia breast cancer, stage iiia fallopian tube cancer, stage iiia ovarian cancer, stage iiia primary peritoneal cancer, stage iiib breast cancer, stage iiib fallopian tube cancer, stage iiib ovarian cancer, stage iiib primary peritoneal cancer, stage iiic breast cancer, stage iiic fallopian tube cancer, stage iiic ovarian cancer, stage iiic primary peritoneal cancer, stage iv fallopian tube cancer, stage iv ovarian cancer, stage iv primary peritoneal cancer